Franklin Resources’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Franklin Resources’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-408,699	Closed	-$2.3M	–	1594
2016 Q1	$2.3M	Sell	408,699 -23,751	-5%	-$308K	﹤0.01%	1239
2015 Q4	$7.44M	Hold	432,450	–	–	﹤0.01%	1059
2015 Q3	$9.13M	Buy	432,450 +87,850	+25%	+$3.01M	﹤0.01%	1037
2015 Q2	$17.1M	Hold	344,600	–	–	0.01%	923
2015 Q1	$27M	Sell	344,600 -12,980	-4%	-$805K	0.01%	820
2014 Q4	$21.7M	Sell	357,580 -44,508	-11%	-$2.24M	0.01%	853
2014 Q3	$17.1M	Buy	402,088 +36,940	+10%	+$1.98M	0.01%	915
2014 Q2	$22.6M	Sell	365,148 -37,650	-9%	-$2.19M	0.01%	834
2014 Q1	$26.2M	Buy	402,798 +170,348	+73%	+$11.5M	0.01%	783
2013 Q4	$13.1M	Buy	232,450 +33,880	+17%	+$1.9M	0.01%	922
2013 Q3	$12.2M	Buy	198,570 +42,020	+27%	+$2.85M	0.01%	927
2013 Q2	$9.16M	Buy	+156,550	New	+$9.63M	0.01%	958

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources's OREX Position: Q2 2016 in Review

Franklin Resources sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 408,699 shares — an estimated $2.3M sold.

Franklin Resources first reported a position in OREX in Q2 2013 and held it in 12 quarters. The position peaked at $27M in Q1 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Franklin Resources reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Franklin Resources sold 408,699 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $2.3M.
Franklin Resources first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
Franklin Resources's Orexigen Therapeutics, Inc. position peaked at $27M in Q1 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Franklin Resources's 13F filing for Q2 2016, filed 11 Aug 2016.